论文信息 - A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL. - 字舞流文

A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL.

J. Byrd | I. Flinn | J. Flynn | R. Furman | S. Stromatt | L. Andritsos | A. Foreno-Torres